by IR Team | Jan 28, 2021 | News
IPM spoke with AXIM Biotech CEO John Huemoeller to see how his firm are going about seeking patent protection for its Covid-19 tests. Obtaining IP rights protections for Covid-19 related treatments and tests is the number one public health priority right now.The race...
by IR Team | Jan 11, 2021 | Press Release
SAN DIEGO, January 11, 2021 — AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced today that it has released a preprint of its...
by IR Team | Dec 15, 2020 | News
In what U.S. FDA commissioner Stephen Hahn billed as “a major milestone” in testing for the COVID-19 pandemic, the FDA has granted an emergency use authorization (EUA) to Ellume Ltd., of East Brisbane, Australia, for the company’s COVID-19 home test. The rapid...
by IR Team | Dec 15, 2020 | News
AXIM Biotechnologies (OTCQB:AXIM -2.4%) has filed an amended Emergency Use Authorization (EUA) application with the FDA. AXIM first filed the EUA in September for measuring COVID-19 neutralizing antibodies in plasma and serum through its rapid diagnostic test. The...
by IR Team | Dec 15, 2020 | Press Release
SAN DIEGO – December 15, 2020 – AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced today that it has filed an amended Emergency Use...
